Substance / Medication

Sargramostim

Overview

Active Ingredient
sargramostim
RxNorm CUI
69634
Labeler: Partner Therapeutics, Inc.Updated: 2024-12-06T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.1 [see Warnings and Precautions ()] Do not administer LEUKINE to patients with a history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factor such as sargramostim, yeast-derived products, or any component of the product. Anaphylactic react

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth Lee, Macdonald John K, McDonald John Wd et al. · Cochrane Database Syst Rev · 2011
PMID: 22071853Meta-Analysis
Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy.
Milkovich G, Moleski R J, Reitan J F et al. · Pharmacotherapy · 2000
PMID: 11130215Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sargramostim (substance)
SNOMED CT
108967001
UMLS CUI
C0216231
RxNorm CUI
69634
Labeler
Partner Therapeutics, Inc.

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.